An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-DFU on wound healing of diabetic neuropathic ulcer (DFU).
Phase of Trial: Phase I/II
Latest Information Update: 20 Nov 2017
At a glance
- Drugs APZ 2 (Primary)
- Indications Diabetic foot ulcer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors RHEACELL
- 16 Oct 2017 Planned End Date changed from 24 Feb 2019 to 1 Apr 2019.
- 16 Oct 2017 Planned primary completion date changed from 24 May 2018 to 1 Jul 2018.
- 25 Sep 2017 The trial has been suspended in Germany.